<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511888</url>
  </required_header>
  <id_info>
    <org_study_id>001-07</org_study_id>
    <nct_id>NCT00511888</nct_id>
  </id_info>
  <brief_title>Nebivolol Versus Carvedilol in Patients With Heart Failure</brief_title>
  <official_title>Effects of Nebivolol Versus Carvedilol in Hypertensive Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND Beta-blockers improve left ventricular (LV) systolic function and prognosis in
      patients with chronic heart failure. Both carvedilol and nebivolol have hemodynamic and
      clinical benefits in chronic heart failure (CHF), but it is unknown whether their pleiotropic
      properties may play a role in different subgroups of patients with CHF.

      OBJECTIVE: To compare the effects of nebivolol and carvedilol on LV function and clinical
      outcome in patients with chronic heart failure and reduced LV systolic function.

      METHODS: 160 hypertensive CHF patients, LV ejection fraction (EF) 40% and in New York Heart
      Association (NYHA) functional class II or III were randomly assigned to receive carvedilol or
      nebivolol therapy for 24 months. At baseline and after 24 months of treatment, all patients
      underwent clinical evaluation: echocardiogram and 6-minute walking test.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    is finish
  </why_stopped>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">160</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Hypertension</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  left ventricular ejection fraction (LVEF) &lt; 40%;

          -  symptomatic heart failure with functional New York Heart Association (NYHA) class II
             or III;

          -  arterial hypertension with systolic blood pressure &gt;140 mmHg and diastolic blood
             pressure &gt;85 mmHg;

          -  clinical stability without hospital admission for heart failure in the previous 3
             months.

        Exclusion Criteria:

          -  history of asthma or severe chronic obstructive pulmonary disease;

          -  severe liver or kidney diseases;

          -  second-degree or third degree heart block without a permanent pacemaker,

          -  sick sinus syndrome, heart rate &lt;60 beat/min, systolic blood pressure &lt;90 mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>53 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>giuseppe rosano, md</last_name>
    <role>Study Director</role>
    <affiliation>IRCCS san Raffaele Cardiovascular Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Rome</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <keyword>chronic heart failure</keyword>
  <keyword>hypertension</keyword>
  <keyword>beta blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

